PF-Atlas › Clinical Trials › NCT01014442

A Study of Mycophenolate Mofetil in Lung Transplant Recipients

mycophenolate mofetil · Phase 3

Registry ID
NCT01014442
Phase
Phase 3
Status
Completed
Drug / intervention
mycophenolate mofetil
Sponsor
Hoffmann-La Roche
Start
2010-01
Enrollment
68
Locations
1

About this trial

This open-label, single center study will assess the pharmacokinetics, efficacy and safety of mycophenolate mofetil in lung allograft recipients. Participants will be split into 2 groups according to the original disease: Group A (cystic fibrosis) and Group B (chronic obstructive pulmonary disease \[COPD\], emphysema, idiopathic pulmonary fibrosis, alpha-1 antitrypsin deficiency \[A1AD\]). All participants will receive mycophenolate mofetil orally, 1.5 grams (g) twice daily (BID) from Day 2 to 30 post transplantation, and 1 g BID from Day 31 to 90 post transplantation. Anticipated time on study treatment is 90 days, and target sample size is 50-100 individuals.

View NCT01014442 on ClinicalTrials.gov →

Explore related

All mycophenolate mofetil trialsAll IPF trials

Related trials

Mycophenolate mofetil — NCT01860183Mycophenolate Mofetil — NCT05785065Mycophenolate mofetil — NCT00883129
Medical disclaimer. This page summarizes public trial data for NCT01014442 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.